XTL Biopharmaceuticals Ltd. is a biopharmaceutical company focused on the acquisition, development, and commercialization of proprietary products and late-stage pharmaceutical product candidates for the treatment of unmet medical needs. The Company is focused on developing therapeutics for the treatment of multiple myeloma (MM), schizophrenia and hepatitis C (HCV).
The Company's lead drug candidate, rHuEPO for the treatment of multiple myeloma blood cancer was granted an orphan drug designation from the FDA. rHuEPO has been approved for marketing by the FDA and has been sold for many years, totaling billions of dollars in sales across the world for the treatment of severe anemia.
XTL is publicly traded on the Tel Aviv Stock Exchange (TASE) and its ADRs are quoted Over-the-Counter on the Pink Sheets in the US (TASE: XTL, OTC: XTLBY).